Skandinaviska Enskilda Banken Ab (Publ) Aerovate Therapeutics, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$17.68 - $29.57 $115,733 - $193,565	-6,546 Reduced 12.87%	44,320 $1.31 Million
Q1 2023 May 11, 2023	SELL	$19.17 - $27.7 $47,426 - $68,529	-2,474 Reduced 4.64%	50,866 $1.03 Million
Q4 2022 Feb 08, 2023	SELL	$15.92 - $30.52 $49,208 - $94,337	-3,091 Reduced 5.48%	53,340 $1.56 Million
Q2 2022 Aug 10, 2022	BUY	$10.8 - $16.91 $457,088 - $715,681	42,323 Added 299.99%	56,431 $882,000
Q1 2022 May 11, 2022	BUY	$8.25 - $18.33 $116,391 - $258,599	14,108 New	14,108 $259,000

28.1M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $65.3M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.